Table 1.
Age (years) | Parameters | No. of Cases (%) |
---|---|---|
median | 55 | |
mean | 56 | |
range | 29–80 | |
Sex | ||
male | 101 (95%) | |
female | 5 (5%) | |
Primary tumor location | ||
Upper | 19 (18%) | |
Middle | 36 (34%) | |
Lower | 51 (48%) | |
T classification | ||
T1 | 42 (40%) | |
T2 | 28 (26%) | |
T3 | 26 (25%) | |
T4 | 10 (9%) | |
N classification | ||
N0 | 70 (66%) | |
N1 | 25 (24%) | |
N2 | 9 (8%) | |
N3 | 2 (2%) | |
7th AJCC Stage | ||
IA | 5 (5%) | |
IB | 33 (31%) | |
IIA | 17 (16%) | |
IIB | 26 (24%) | |
IIIA | 11 (10%) | |
IIIB | 3 (3%) | |
IIIC | 9 (9%) | |
IV | 2 (2%) | |
Histological grading | ||
Grade 1 | 10 (9%) | |
Grade 2 | 70 (66%) | |
Grade 3 | 26 (25%) | |
Surgical margin | ||
Negative | 91 (86%) | |
Positive | 15 (14%) | |
UTX expression | ||
Low expression | 62 (58%) | |
High expression | 44 (42%) | |
E-cadherin | ||
Low expression | 50 (47%) | |
High expression | 56 (53%) |
AJCC, American Joint Committee on Cancer.